StockNews.AI
ICLR
StockNews.AI
104 days

Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

1. ICON plc released survey findings on multi-indication cardiometabolic R&D. 2. 155 professionals contributed insights on obesity therapies and related comorbidities.

2m saved
Insight
Article

FAQ

Why Bullish?

The survey on cardiometabolic R&D indicates strong potential for growth in obesity treatment, which could add revenue streams for ICLR.

How important is it?

The exploration of therapeutic pathways for obesity aligns with market needs, increasing ICLR's service demand.

Why Long Term?

Increased investment in multi-indication studies indicates sustained demand for ICLR's capabilities over time.

Related Companies

VRTXREGNPFE
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the pote.

Related News